AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Nasal Decongestant to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having Anesthesia.

RecruitingPhase 4Ages 1 Year - 8 YearsAllTelethon Kids Institute
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this multicentre, double-blind, randomised controlled trial study is to learn if the use of a nasal spray to open the nasal passages and increase airflow before surgery can reduce the occurrence of perioperative respiratory adverse events in children with upper respiratory tract infection who are undergoing anesthesia. The main questions it aims to answer are: * Does use of a nasal decongestant (Oxymetazoline 0.05%) reduce perioperative respiratory adverse events during emergence (when waking up from anesthesia) or in the post-anesthesia care unit in children. * Is it easy and acceptable to doctors, children and parents to use the nasal decongestant treatment? Researchers will compare the nasal decongestant to a placebo (a look-alike substance that contains no drug) to see if it works to reduce perioperative respiratory adverse effects. Participants will: * Take a nasal d

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Children aged 1 to 8.99 years with a current or recent upper respiratory tract infection (\<2 weeks). * Undergoing interventions or surgery under general anesthesia (elective or urgent not emergency). Exclusion Criteria: * Currently taking nasal decongestants (past 24 hours) or receiving co-phenylocaine or decongestion for surgery. * Surgery impacting the nasal airflow, e.g. adenoidectomy, cautery of inferior turbinates. * Airway management with an endotracheal tube, face mask or high flow nasal oxygen. * Known cardiovascular, respiratory or neurological disorders giving an ASA III or above. * Thyroid disease. * Diabetes. * Known hypersensitivity to the interventional products. * Department of Child Protection and Family Services involved in their care. * Planned admissions to the Paediatric Intensive Care Unit (PICU).
๐Ÿ’Š

What it tests

  • Decongestant nasal spray (oxymetazoline hydrochloride (0.05%))
  • PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02%
๐Ÿ“

Where

1 site
Perth Children's Hospital
Perth, Australia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy